News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
75 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44432)
2016 (38329)
2017 (37188)
2018 (39119)
2019 (51334)
2020 (57663)
2021 (58720)
2022 (53928)
2023 (42564)
2024 (37441)
2025 (33091)
2026 (15754)
Month
January (2433)
February (2866)
March (3029)
April (3115)
May (3357)
June (954)
Day
1 (26)
2 (174)
3 (177)
4 (143)
5 (222)
6 (34)
9 (203)
10 (137)
11 (95)
12 (124)
13 (105)
15 (21)
16 (103)
17 (104)
18 (170)
19 (133)
20 (75)
22 (7)
23 (133)
24 (158)
25 (111)
26 (117)
27 (109)
30 (214)
31 (134)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
Day
1
2
3
4
5
6
9
10
11
12
13
15
16
17
18
19
20
22
23
24
25
26
27
30
31
Spinal muscular atrophy
Roche Ends Run for Muscular Atrophy Drug, Leaving Door Open for Competitors
The main beneficiary of Roche’s discontinuation of an investigational spinal muscular atrophy drug is Scholar Rock, which was hobbled by manufacturing concerns at a Novo Nordisk facility last year but is now nearing a potential resolution.
March 20, 2026
·
2 min read
·
Tristan Manalac
Breast cancer
Novartis Buys Breast Cancer Drug for $2B to Keep Up With Myriad Rivals
Aside from the $2 billion upfront payment, Novartis is also putting up to $1 billion on the line in milestones for Synnovation Therapeutics’ pan-mutant-selective PI3Kα blocker.
March 20, 2026
·
2 min read
·
Tristan Manalac
Approvals
Rhythm Bounces Back from Phase 3 Fail with FDA Nod for Rare Obesity Injection
At its peak, Imcivree’s sales in hypothalamic obesity could reach over $2 billion worldwide, according to analysts at Stifel.
March 20, 2026
·
2 min read
·
Tristan Manalac
Policy
Biopharma Could Provide a Haven for Investment as Middle East Conflict Roils Global Markets
Biotech, in particular companies that are pre-commercial with a longer-duration risk profile, could be great investments as Operation Epic Fury rolls on, according to a Truist Securities analysis.
March 20, 2026
·
2 min read
·
Annalee Armstrong
Government
HHS Denies Disbandment of CDC Vaccine Advisory Group in Wake of Court Ruling
A spokesperson for the Department of Health and Human Services refuted the claim, made Thursday on social media by ACIP Vice Chair Robert Malone, calling it “baseless speculation.”
March 20, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 20, 2026
·
14 min read
Press Releases
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 20, 2026
·
11 min read
Press Releases
Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
March 20, 2026
·
12 min read
Press Releases
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
March 20, 2026
·
11 min read
Press Releases
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
March 20, 2026
·
19 min read
1 of 8
Next